Valeant New CEO Papa Sees ‘Speed Bumps’ in Dermatology

  • Papa says finances must be centralized, hired new controller
  • New CEO promises more transparency after months of turmoil

Andrew Left: Valeant May See Higher Before It Sees Lower

Valeant Pharmaceuticals International Inc.’s new Chief Executive Officer, Joe Papa, said that while there’s more work to do in dermatology, the company has a “very good pipeline” of new drugs that hasn’t been fully appreciated.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.